IBD

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Retrieved on: 
Wednesday, March 27, 2024
Community, Patient, Colostomy, Health care, Bacteria, Quality of life, Shoe, Curriculum, Western world, Abdominal pain, IBD, Immune system, Diarrhea, Disease, Health professional, Crohn's disease, Student, Environment, Caregiver, Incidence, Empathy, Abdomen, Inflammatory bowel disease, HY

DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.

Key Points: 
  • DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE.
  • While inflammation is the body's natural reaction to irritation or injury, in patients with IBD, it is thought that the body's own immune system mistakenly identifies a harmless food or bacteria within the gut as 'foreign' and attacks it3.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Although the simulation couldn't fully replicate the experience, it is meant to foster empathy for individuals living with IBD.

WealthFeed Secures $2 Million of Funding to Launch its Direct-to-Advisor AI-Powered Money-in-Motion Platform

Retrieved on: 
Tuesday, March 12, 2024
Registered investment adviser, Database, Private equity, Entrepreneurship, Intelligence, Service provider, Catalysis, AI, Investment banking, IBD, RIA, RIAS, Adviser

NEW YORK, March 12, 2024 /PRNewswire/ -- WealthFeed Inc ("WealthFeed"), the cutting-edge AI-powered organic growth platform for Financial Advisors, proudly announces the successful closure of a $2 million funding round.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- WealthFeed Inc ("WealthFeed"), the cutting-edge AI-powered organic growth platform for Financial Advisors, proudly announces the successful closure of a $2 million funding round.
  • Strategic investors include Thicket Ventures and executives from the Registered Investment Advisor (RIA), Investment Banking and Private Equity sectors.
  • The platform boasts a dynamic money-in-motion prospect database, offering Advisors extensive filtering capabilities to identify high-converting prospect opportunities, in real time.
  • "The trust demonstrated by our investors validates the exciting potential of our WealthFeed platform.

Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africa

Retrieved on: 
Friday, March 15, 2024
Disease, Caregiver, Abdominal pain, Empathy, Patient, Common, Gastrointestinal tract, Weight loss, Knowledge, Diarrhea, IBD, Shoe, Crohn's disease, Inflammatory bowel disease, Immune system, Ulcerative colitis, Fatigue, Pharmaceutical industry

JOHANNESBURG, March 12, 2024 /PRNewswire/ -- Takeda, the patient-focused biopharmaceutical firm, introduced its worldwide 'In Their Shoes' initiative to Johannesburg, South Africa. This effort, aimed at increasing awareness about the challenging symptoms of Inflammatory Bowel Disease (IBD), involved an immersive two-day simulation that provided profound insights into the impact of the disease on patients' daily lives.

Key Points: 
  • Takeda's 'In Their Shoes' program sheds light on the daily challenges faced by individuals with IBD in South Africa, promoting empathy and awareness
    JOHANNESBURG, March 12, 2024 /PRNewswire/ -- Takeda, the patient-focused biopharmaceutical firm, introduced its worldwide 'In Their Shoes' initiative to Johannesburg, South Africa.
  • [1] Whether Crohn's Disease or Ulcerative Colitis, IBD rates are increasing in South Africa.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Ursula Myles, Country Manager for South Africa, at Takeda, said, "At Takeda, our commitment to addressing life-limiting gastrointestinal diseases is unwavering.

Capital Digestive Care Launches AI-Driven LGI-Flag Algorithm for Predicting Lower Gastrointestinal Disorders Including Colorectal Cancer in the United States

Retrieved on: 
Tuesday, March 12, 2024
Colonoscopy, Disease, Colorectal cancer, Risk, USPSTF, Patient, CBC, Roche, FIT, Capital, Mid-Atlantic (United States), United, IBD, Inflammatory Bowel Diseases, Woman, Excellence, IBS, EHR

Available through the Roche navify Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.

Key Points: 
  • Available through the Roche navify Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.
  • "Capital Digestive Care is committed to enabling the digital transformation of healthcare, in order to provide a more personalized, convenient and predictive continuum-of-care for patients," said Michael Weinstein, M.D., CEO of Capital Digestive Care.
  • Now, we have a means to more precisely identify those at high risk of lower GI disorders, including colorectal cancer so they may avoid the devastating effects of the disease through increased screening and earlier detection and treatment."
  • "This helps advance that mission by offering a highly effective and clinically validated machine-learning-based algorithm to identify those at increased risk of a wide array of lower GI disorders, including colorectal cancer."

Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in Amylyx Pharmaceuticals, Inc. (AMLX) Securities Class Action

Retrieved on: 
Monday, March 11, 2024
Court, ALS, District court, AMX0035, Patient, IBD, Evercore, Amyotrophy, Pharmaceutical industry

Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for Amyotrophic Lateral Sclerosis (“ALS”) and other neurodegenerative diseases.
  • The Company’s products include, among others, AMX0035 (commercially referred to as “RELYVRIO” in the U.S.), for the treatment of ALS.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024
Uber, News, Neurobiology of Aging, Form, Apoptosis, IPO, Health, Particulates, Cassava Sciences, City University, P.C, Electrode, ALS, Register, Initiative, Cassava, AMX0035, Journal, Graphite, IBD, Evercore, EAF, Amyotrophy, Environment, DoorDash, Complaint, Safety, Biomarker, Public expenditure, Sustainable development, Amylyx Pharmaceuticals, Science, Prescription, Prospectus, GrafTech, Reuters, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Government, Patient, Cognition, Defendant, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Thursday, March 7, 2024
Pomerantz, Court, ALS, Person, Prior, Food, Complaint, District court, Apoptosis, Ext, AMX0035, Patient, LLP, IBD, Evercore, Action Replay, Amyotrophy, Prescription, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Thursday, March 7, 2024
Court, BBC World Service, Advertising, Investor's Business Daily, Patient, Amylyx Pharmaceuticals, LLP, IBD, Evercore, Prescription, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, Amylyx, Sunnova, and DICK’S Sporting Goods and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 5, 2024
News, Neurobiology of Aging, Commerce, Apoptosis, The Washington Free Beacon, Energy, Sunnova, DOE, Cassava Sciences, State, City University, P.C, House Committee, ALS, Initiative, Cassava, AMX0035, Journal, Electricity, IBD, Evercore, Amyotrophy, Complaint, Safety, NOVA, Biomarker, Amylyx Pharmaceuticals, Outdoor, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, DKS, FDA, Food, Data management, Investor's Business Daily, Nature, Letter, Risk, Natural Resources, Patient, Cognition, Defendant, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Then, on August 22, 2023, Dick’s Sporting Goods revealed that profitability for the second quarter of 2023 was significantly lower than previously represented.
  • Dick’s Sporting Goods also lowered its profitability guidance for the rest of fiscal year 2023.
  • For more information on the DICK’S Sporting Goods class action go to: https://bespc.com/cases/DKS

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Friday, March 1, 2024
Court, BBC World Service, Advertising, Investor's Business Daily, Patient, Amylyx Pharmaceuticals, LLP, IBD, Evercore, Prescription, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).